公开(公告)号：US20190315738A1

公开(公告)日：2019-10-17

申请号：US16311654

申请日：2017-06-20

申请人： DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION

发明人： Hwan Geun Choi ,  Jung Beom Son ,  Shinae Kim ,  Seungyeon Lee ,  Eunhwa Ko ,  Joongheui Cho ,  Seock Yong Kang ,  So Young Kim ,  Jin-Hee Park ,  Yi Kyung Ko ,  Hee Yoon Ryu ,  Nam Doo Kim ,  Hyunkyoung Kim ,  Younho Lee ,  Sun-Hwa Lee ,  Dayea Kim ,  Sun Joo Lee ,  Seongho Hong ,  Sang Hyun Min ,  Sungwoo Lee ,  Dong Kyu Choi ,  Jae Hyun Bae ,  Eunmi Hong ,  Tae-ho Jang ,  Jaeyoung Song ,  Sangbum Kim ,  Suk Kyoon Yoon

IPC分类号： C07D471/04 ,  C07D519/00 ,  A23L29/00

摘要： The present invention relates to a novel imidazopyridine derivative, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer. The novel imidazopyridine derivative according to the present invention, a stereoisomer thereof and a pharmaceutically acceptable salt thereof can effectively inhibit cancer-related kinases, are excellent in inhibiting proliferation of cancer cells in a cancer cell line, and effectively inhibit proliferation of cancer cells (cancer cell apoptosis) in a cancer cell heterograft model, and thus can be useful as a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer.Also, the novel imidazopyridine derivative according to the present invention, the stereoisomer thereof, and the pharmaceutically acceptable salt thereof can effectively inhibit Src and Fyn, thereby being useful as a pharmaceutical composition for preventing or treating the Src and Fyn related diseases, and in particular, have been confirmed to be useful in diabetic nephropathy in animal model experiments. Therefore, the compound of the present invention can be effective as a pharmaceutical composition containing the same as an active ingredient for preventing or treating diabetic nephropathy.